“We expect to consummate the business combination during the first quarter of 2025 and will faithfully carry out the process for completing the business combination, and grow CubeBio into a global company by increasing corporate value,” said CubeBio CEO Eun-jong Choi.
CubeBio $375M Merger : Mountain Crest’s Track Record with SPAC Mergers
Mountain Crest V is the fifth in the Mountain Crest series of special purpose acquisition companies (SPACs). These entities raise capital through IPOs with the intention of acquiring private companies and taking them public. Once the merger is complete, the target company assumes the SPAC’s stock listing, allowing for a seamless transition to a publicly traded entity.
Suying Liu, Chairman, CEO, and CFO of Mountain Crest V, expressed enthusiasm about the upcoming merger: “CubeBio’s diagnostic innovation, non-invasive productization and active commercialization present significant growth potential. We are excited to be working with CubeBio on this proposed business combination.”
